BrightGene Bio-Medical Technology
BrightGene Bio-Medical Technology Co., Ltd., commonly referred to as BrightGene, is a leading biopharmaceutical company headquartered in China. Established in 2003, BrightGene has made significant strides in the biotechnology sector, focusing on the research, development, and manufacturing of innovative therapeutics and active pharmaceutical ingredients (APIs). With a strong presence in both domestic and international markets, BrightGene excels in the fields of oncology, infectious diseases, and metabolic disorders. The company is renowned for its unique approach to drug development, leveraging advanced technologies to create high-quality, cost-effective solutions. Notable achievements include successful collaborations with global pharmaceutical firms and a robust pipeline of proprietary products, positioning BrightGene as a key player in the biomedicine landscape.
DitchCarbon Score
How does BrightGene Bio-Medical Technology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BrightGene Bio-Medical Technology's score of 1 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
BrightGene Bio-Medical Technology's reported carbon emissions
BrightGene Bio-Medical Technology, headquartered in CN, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or climate pledges outlined in their initiatives. Without concrete figures or commitments, it is challenging to assess their carbon footprint or climate strategy. However, the absence of data may indicate a need for enhanced transparency in their environmental impact reporting. As the industry increasingly prioritises sustainability, BrightGene's future climate commitments will be crucial in aligning with global efforts to reduce greenhouse gas emissions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
BrightGene Bio-Medical Technology is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
